Academic journal article Bulletin of the World Health Organization

New Hepatitis C Recommendations

Academic journal article Bulletin of the World Health Organization

New Hepatitis C Recommendations

Article excerpt

Patients with hepatitis C virus infection should be treated--whenever possible with direct-acting antivirals rather than interferon-containing regimens that were previously recommended, according to updated WHO recommendations published last month.

This is one of several recommendations in Guidelines for the screening, care and treatment of persons with hepatitis C infection.

Since the document was first issued in 2014, many new drugs have been licensed for hepatitis C virus infection and some of them were included in the latest WHO Model list of essential medicines released last year.

The updated guidelines for the treatment of hepatitis C virus infection reflect these changes and include new evidence-based recommendations.

"These medicines are transforming the treatment of hepatitis C virus infection, enabling the use of regimens that can be administered orally, [that] are shorter in duration (as short as eight weeks), [and that] result in cure rates higher than 90%, and are associated with fewer serious adverse events," according to the updated guidelines.

The updated guidelines no longer recommend treatment with first-generation protease inhibitors, telaprevir and boceprevir, as these two medicines are less effective than newer medicines and have more frequent adverse effects. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.